
zzso melanoma, the most common zzso of the eye, has a 50% rate of liver zzso among patients with large primary zzso Several therapies prolong survival of zzso zzso however, none are zzso and no patients zzso zzso we are exploring zzso as an alternative or zzso zzso zzso melanoma may be particularly appropriate for zzso because primary tumors arise in an zzso site and may express zzso to which the host is not zzso We are developing zzso class II zzso zzso zzso zzso zzso melanoma vaccines that activate zzso T zzso which are key cells for zzso zzso zzso zzso zzso immune memory, and preventing zzso Our previous studies showed that tumor cells genetically modified to express zzso and zzso II molecules zzso to the recipient are potent zzso of zzso zzso Because the zzso zzso zzso vaccines do not express the accessory zzso zzso chain, they present zzso zzso peptides derived from zzso zzso tumor zzso We now report that zzso zzso zzso vaccines, prepared from primary zzso zzso that arise in the zzso eye, prime and boost zzso zzso T cells from the peripheral blood of either healthy donors or zzso melanoma patients that zzso with primary zzso zzso from other patients and zzso zzso In contrast, vaccines prepared from zzso cells in the liver are less effective at zzso zzso T cells, suggesting that tumor cells originating in zzso sites may have enhanced capacity for inducing zzso immunity and for serving as zzso zzso 

